Insights into superoxide dismutase 3 in regulating biological and functional properties of mesenchymal stem cells

Cell & Bioscience
Shyam Kishor SahTae-Yoon Kim

Abstract

Mesenchymal stem cells (MSCs) have been extensively studied and implicated for the cell-based therapy in several diseases due to theirs immunomodulatory properties. Embryonic stem cells and induced-pluripotent stem cells have either ethical issues or concerns regarding the formation of teratomas, introduction of mutations into genome during prolonged culture, respectively which limit their uses in clinical settings. On the other hand, MSCs also encounter certain limitation of circumscribed survival and reduced immunomodulatory potential during transplantation. Plethora of research is undergoing to improve the efficacy of MSCs during therapy. Several compounds and novel techniques have been employed to increase the therapeutic potency of MSCs. MSCs secreted superoxide dismutase 3 (SOD3) may be the mechanism for exhibiting direct antioxidant activities by MSCs. SOD3 is a well known antioxidant enzyme and recently known to possess immunomodulatory properties. Along with superoxide scavenging property, SOD3 also displays anti-angiogenic, anti-chemotactic and anti-inflammatory functions in both enzymatic and non-enzymatic manners. In this review, we summarize the emerging role of SOD3 secreted from MSCs and SOD3's effects during cel...Continue Reading

References

Sep 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·K HjalmarssonT Edlund
Sep 17, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·H Ulrich HinkTohru Fukai
Jan 23, 2004·The Journal of Biological Chemistry·Steen V PetersenJan J Enghild
Jul 1, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Yi ChuDonald D Heistad
Dec 16, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Oliver JungRalf P Brandes
Oct 27, 2007·Antioxidants & Redox Signaling·Corrine R KlimentTim D Oury
Dec 24, 2009·Journal of Neurochemistry·Kevin KempAlastair Wilkins
Apr 9, 2011·Antioxidants & Redox Signaling·Tohru Fukai, Masuko Ushio-Fukai
Apr 21, 2012·Current Molecular Medicine·M P De MiguelF Arnalich-Montiel
Jul 6, 2012·Journal of Dermatological Science·Myung-Ja KwonTae-Yoon Kim
Dec 12, 2012·The Journal of Investigative Dermatology·Yun Sang LeeTae-Yoon Kim
Apr 26, 2013·Stem Cells and Development·Jaime DeSantiagoKathrin Banach
Jun 6, 2013·Acta Pharmacologica Sinica·Xin WeiYu-fang Shi
Nov 5, 2013·Cell Death and Differentiation·S MaY Wang
Feb 28, 2014·The Journal of Investigative Dermatology·Laurence DenatZalfa A Abdel-Malek
Jan 27, 2015·Current Cancer Drug Targets·Astra I ChangJian Wu
May 29, 2015·International Journal of Stem Cells·Nayoun Kim, Seok-Goo Cho
Jun 15, 2016·Stem Cells·Dongsheng JiangKarin Scharffetter-Kochanek
Sep 17, 2016·American Journal of Respiratory Cell and Molecular Biology·Sailaja GhantaMark A Perrella
May 10, 2017·Balsaeng'gwa saengsig·Hee Jung Kim, Jeong-Soo Park

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation
SMA

Software Mentioned

ESPript
CLUSTALW
ENDscript

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.